Consensus Report
GLP-1 Agonists
Moderate Consensus
out of 5
Based on 61 videos (84 hours analyzed) across 5 experts · Updated 2026-03-19
Expert Positions
The Verdict
This is one of the most polarizing topics across our expert panel. Attia and Huberman see GLP-1 agonists as powerful tools when combined with exercise and high protein intake, while Hyman strongly opposes their widespread use, arguing they mask root causes and create pharmaceutical dependency. This is a prescription medication, not a supplement — use requires physician oversight.
Where They Disagree
Attia views GLP-1 agonists as powerful, appropriate tools for weight management when combined with exercise and nutrition — while Hyman argues they mask root causes, create lifelong pharmaceutical dependency, and do not address the toxic food environment driving metabolic disease.
Attia's position on GLP-1s has evolved significantly over time and he now sees them more favorably, while Hyman has become increasingly critical, particularly regarding their use in children and as a substitute for dietary intervention.
+ 2 more disagreements in the full report
About This Analysis
This consensus report on GLP-1 Agonists is based on 61 videos (84 hours analyzed) from five longevity experts: Andrew Huberman, Peter Attia, Rhonda Patrick, Bryan Johnson, and Mark Hyman. Each expert's position was independently analyzed from their published video content, including lectures, podcast episodes, and Q&A sessions with 1,000+ guest scientists.
The full report includes 8 key findings, dosage and protocol details, expert deep dives with direct video citations and timestamps, risk considerations, and related supplement synergies.
Unlock the Full Report
Get dosages, timing protocols, expert deep dives with video citations, and risks for GLP-1 Agonists.
Every recommendation traces back to a specific expert, video, and timestamp.
$9/month or $79/year · Cancel anytime